Investigator Agreement Template for Switzerland

An Investigator Agreement is a fundamental legal contract that governs the relationship between sponsors, contract research organizations (CROs), and principal investigators conducting clinical trials in Switzerland. This document ensures that all parties understand their roles, responsibilities, and obligations when conducting human research studies under Swiss law.

When do you need this document?

You need an Investigator Agreement whenever a pharmaceutical company, medical device manufacturer, or CRO engages a principal investigator to conduct a clinical trial in Switzerland. This applies to studies conducted in hospitals, academic medical centers, or private research facilities. The agreement is mandatory before any research activities begin and must be in place before ethics committee review. You'll also need this document when establishing multi-center trials involving multiple investigators, when conducting investigator-initiated studies with industry sponsorship, or when transferring clinical trial responsibilities between investigators.

Key legal considerations

The agreement must clearly define each party's responsibilities regarding protocol compliance, patient safety monitoring, and adverse event reporting. Critical clauses include intellectual property rights allocation, data ownership and sharing provisions, and confidentiality obligations protecting proprietary information and patient data. Financial arrangements, including investigator compensation, site fees, and expense reimbursement, must be transparently documented to avoid conflicts of interest. The contract should address liability allocation, insurance requirements, and indemnification provisions protecting investigators and institutions. Quality assurance obligations, including monitoring visits, audit rights, and record retention requirements, must be clearly specified to ensure regulatory compliance.

Legal requirements in Switzerland

Swiss law requires strict compliance with the Human Research Act (HRA) and Clinical Trials Ordinance (ClinO), which mandate specific investigator qualifications, training requirements, and ongoing responsibilities. The agreement must ensure compliance with the Swiss Federal Act on Data Protection (FADP), particularly regarding patient consent, data processing, and cross-border data transfers. Ethics committee approval must be obtained before study initiation, and the agreement should reference ongoing compliance obligations. Swissmedic notification and oversight requirements apply to medicinal product studies, requiring specific regulatory reporting procedures. The contract must align with Swiss Code of Obligations principles governing contractual relationships and include dispute resolution mechanisms under Swiss jurisdiction. Additionally, the agreement must address Swiss-specific requirements for investigator insurance, site qualification standards, and local reporting obligations to cantonal authorities.